期刊文献+

糖心通对糖尿病性心脏病的保护性机制临床研究 被引量:2

Clinical Study on the Protective Mechanisms of Diabetes Heart Disease by Tangxintong
下载PDF
导出
摘要 目的:观察糖心通对糖尿病性心脏病的保护作用,并对其机制进行临床研究。方法:将120例糖尿病性心脏病患者随机分为治疗组和对照组。其中治疗组用糖心通合剂治疗观察60例,对照组用糖脉康治疗观察60例。治疗8周后观察患者的症状、体征并检测心肌供血、血糖、HbAlc、胰岛素水平、血浆高同型半胱氨酸(HcyM)、脂联素(APN)等指标。结果:临床观察发现,糖心通不但可有效的改善糖尿病性心脏病患者的症状、体征,改善患者心肌供血,而且可显著降低血糖、HbAlc和胰岛素水平,明显改善血浆高同型半胱氨酸(HcyM) 、脂联素(APN),与治疗前比有显著性差异,且明显优于对照组。结论:糖心通对糖尿病性心脏病有显著的防治作用,值得进一步推广和研究。 Objective: To observation the protective function of Tangxintong to diabetes heart disease,and conducts the clinical research to its mechanism.Methods: Considering the basis of above,we organize Tangxintong.And then we take the Clinical Research.Clinical research:120 cases of Diabetic Cardiopathy were randomly divided into treatment and control groups.The treatment group with 60 cases was given Tangxintong and the control group wih 60 cases was given Tangmaikang.After 8 weeks,the experiment index were compared to those in begining.Results: The clinical observation discovery,the sugar regards clear not only may the effective improvement diabetes patient's symptom,the body draft,improves the function of the heart,moreover may remarkably reduce the blood sugar and HbA1c,obviously im-proves the blood to change,especially to patient's level of blood adiponectin、hyperhomocysteinemia、IL-18 has the remarka-ble improvement,compared to has significance the difference with the treatment before,also obviously surpasses thecomparison group.Conclusion:The Tangxintong has the remarkable prevention function to the diabetes heart disease.It is worth further promoting and studying.
出处 《中国医药导刊》 2009年第1期37-39,共3页 Chinese Journal of Medicinal Guide
基金 山东省中医管理局批准山东省中医药科技发展计划(课题号:950431)
关键词 糖心通 糖尿病性心脏病 临床研究 Tangxintong Diabetes Heart Disease Clinical Study
  • 相关文献

参考文献12

二级参考文献38

  • 1黄勤,郭志勇,邹大进,高从容,徐茂锦,陈月,冯正康.肥胖及2型糖尿病患者血清脂联素水平测定及其临床意义[J].中华糖尿病杂志(1006-6187),2004,12(4):260-261. 被引量:11
  • 2李光伟,Step.,L.检测人群胰岛素敏感性的一项新指数[J].中华内科杂志,1993,32(10):656-660. 被引量:2125
  • 3潘长玉,中国区合作调查组.中国糖尿病控制现状——指南与实践的差距 亚洲糖尿病治疗现状调查1998,2001及2003年中国区结果介绍[J].国外医学(内分泌学分册),2005,25(3):174-178. 被引量:395
  • 4程汉桥.糖尿病患者中医证型与血液流变学的相关性研究[J].中国中西医结合杂志,1998,(1):11-11.
  • 5-.第二届全国活血化瘀研究学术会议.血瘀证诊断标准[J].中西医结合杂志,1987,7(3):129-129.
  • 6Hanson NQ, Aras O, Yang F, et al. C677 T and A1289 C polymorphisms of the methylenetetrahydrofolate reductase gene: incidence and effect of combined genotypes on plasma fasting and postmethionine load homocysteine in vascular disease. Clinical Chemistry,2001,47: 661-666.
  • 7Fanapour PC, Yug B, Kochar MS. Hyperhomocysteinemia: an additional cardiovascular risk factor,WMJ,1999,98:51-54.
  • 8Smulders YM, Rakie M, Slaats EH, et al. Fasting and postmethionine homocysteine level in NIDDM Determinants and correlations with retinopathy, albuminuria,and cardiovascular disease. Diabetes Care, 1999,22:125-132.
  • 9Okada E, Oida K, Tada H, et al. Hyperhomocysteinemia is a risk factor for coronary arteriosclerosis in Japanese patients with type 2 diabetes. Diabetes Care, 1999,22: 484-490.
  • 10Fonseca VA, Mudaliar S, Schmidt B, et al. Plasma homcysteine concentrations are regulated by acute hyperinsulinemia in nondiabetic but not type 2 diabetic subjects. Metabolism, 1998,47 : 686-689.

共引文献106

同被引文献119

引证文献2

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部